Deborah Shenkman, RDLD, CDCES

The panel concludes its discussion with key takeaways on the optimal care of patients with type 1 diabetes care and thoughts on unmet needs within the treatment space.

Focusing on logistical matters as it pertains to teplizumab administration, the panel discusses infusion site considerations, insurance coverage hurdles, and the process of getting patients approved.

Diabetes specialists outline the patient selection protocol for teplizumab and describe the teplizumab infusion process.

Experts on type 1 diabetes discuss the availability of local medical facilities that offer teplizumab screening and evaluation services for individuals at risk of progression of disease.

Amy Burton, MD, reviews findings from the TN-10 study investigating teplizumab, an anti-CD3 monoclonal antibody, for prevention of diabetes in relatives at risk for T1D.

Diabetes experts discuss the important role of teplizumab in delaying the onset of type 1 diabetes and provide insights on the drug’s mechanism of action.

Following audience polls, the panelists provide clinical insights into their screening practices for patients with type 1 diabetes, highlighting key antibodies they screen for.

Audience polls provide the panel insights into common screening practices for patients with type 1 diabetes.

The panel outlines the stages of type 1 diabetes, focusing on the importance of early intervention to prevent complications of the disease.

A panel of experts on type 1 diabetes (T1D) describe the prevalence and burden of the disease, highlighting the emotional and socio-economic burden extending beyond medical expenses.